Bio Vantage

Bio Vantage
Contributor since: 2012
Company: Biovantage Investments
Gilead's 12-month Price Target At $84
Johnson & Johnson's 12-month Price Target At $105
Acadia Stock Report: Stock Valuation
3 Sources Of Revenue For Incyte
How Much Should You Pay For Incyte?
Novartis: Financial Projection And Stock Valuation
Novartis: 5-Year Revenue Outlook
Is Pfizer Overvalued At $28.5?